KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Short term Debt (2020 - 2025)

Fulgent Genetics' Short term Debt history spans 6 years, with the latest figure at $28.1 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 1.94% year-over-year to $28.1 million; the TTM value through Dec 2025 reached $28.1 million, up 1.94%, while the annual FY2025 figure was $28.1 million, 1.94% up from the prior year.
  • Short term Debt for Q4 2025 was $28.1 million at Fulgent Genetics, down from $28.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $45.3 million in Q2 2021 and bottomed at $10.0 million in Q4 2021.
  • The 5-year median for Short term Debt is $24.5 million (2023), against an average of $22.3 million.
  • The largest annual shift saw Short term Debt soared 5305.41% in 2021 before it plummeted 50.07% in 2023.
  • A 5-year view of Short term Debt shows it stood at $10.0 million in 2021, then grew by 8.95% to $10.9 million in 2022, then skyrocketed by 108.35% to $22.7 million in 2023, then grew by 21.63% to $27.6 million in 2024, then grew by 1.94% to $28.1 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Short term Debt are $28.1 million (Q4 2025), $28.5 million (Q3 2025), and $27.6 million (Q2 2025).